Overexpression of Fc mu receptor (FCMR, TOSO) gene in chronic lymphocytic leukemia patients.
Rai and Binet staging systems that have been used as a standard method for evaluating the prognosis of chronic lymphocytic leukemia (CLL) have some restrictions in distinguishing the early stage CLL patients that will progress rapidly. To solve this shortcoming, prognostic parameters other than staging have become important in the recent years. Intracellular upregulation of Fc mu receptor (FCMR, FAIM3/TOSO) gene in the leukemic lymphocytes of the patients with CLL may be an important parameter in predicting the progression of the disease. In this study, FCMR mRNA expression levels were evaluated in 50 CLL patients and in 50 healthy controls. FCMR mRNA expression was found to be significantly higher in CLL patients than in healthy controls. We, then, evaluated FCMR mRNA levels according to the stages of CLL. Rai stage 0, I, II cases were compared with stage III and IV, and Binet A was compared with Binet B and C according to FCMR mRNA levels. In cases with higher risks, Rai stage III, IV and Binet stage B and C, FCMR mRNA levels were also significantly higher. In addition, overexpression of the FCMR seems to be promoting the chromosomal abnormalities. As a result, we found that the mRNA levels of FCMR in the CLL patients are 23-fold higher than that of the control group and this may suggest that it can be associated with the disease progression and survival. For this reason and because of the simplicity of analyzing with Q-PCR, it can be a useful clinical parameter, after its importance has been shown in larger and multi-variate studies.
Department of Medical Biology and Genetics, Istanbul Bilim University, Buyukdere Cad No:120 Esentepe, 34394 Istanbul, Turkey. vshancer@istanbul.edu.tr
Veysel Sabri
VS
Hancer
Reyhan
R
Diz-Kucukkaya
Melih
M
Aktan
D000368:Aged; D051017:Apoptosis Regulatory Proteins / Q000235:genetics*; D016022:Case-Control Studies; D002869:Chromosome Aberrations; D017931:DNA Primers / Q000737:chemistry / Q000235:genetics; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000473:pathology*; D008214:Lymphocytes / Q000378:metabolism / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
D051017:Apoptosis Regulatory Proteins; D017931:DNA Primers; C112037:FCMR protein, human; D008565:Membrane Proteins; D012333:RNA, Messenger
Blood. 1999 Sep 15;94(6):1840-7
10477712
Blood. 2008 Nov 15;112(10):4213-9
18708628
Nat Immunol. 2000 Nov;1(5):441-6
11062505
Leuk Res. 2006 Apr;30(4):415-26
16181674
Immunity. 1998 Apr;8(4):461-71
9586636
Biochem Biophys Res Commun. 2007 Aug 3;359(3):723-8
17553462
Lancet. 2004 Jan 10;363(9403):105-11
14726163
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
J Clin Oncol. 1999 Jan;17(1):399-408
10458259
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
12434020
Immunol Lett. 2005 Feb 15;97(1):131-9
15626485
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
16166262
Int Immunol. 2010 Mar;22(3):149-56
20042454
J Exp Med. 2001 Dec 3;194(11):1625-38
11733577
J Clin Invest. 2005 Mar;115(3):755-64
15711642
Blood. 2008 Jun 15;111(12):5446-56
18216293
Blood. 2008 Jul 15;112(2):394-7
18434611
J Exp Med. 2001 Dec 3;194(11):1639-47
11733578
J Biol Chem. 2005 Mar 11;280(10):9618-26
15632112
Scand J Immunol. 2009 Sep;70(3):206-15
19703010
N Engl J Med. 2004 Aug 26;351(9):893-901
15329427
J Exp Med. 2009 Nov 23;206(12):2779-93
19858324